


Appl. No. 10/639,948  
Confirmation No. 6989  
Preliminary Amendment dated July 11, 2005

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective amount of a combination of a compound selected from the group consisting of pyridoxal-5'-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, and a therapeutic cardiovascular compound selected from the group consisting of ~~an angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist,~~ a calcium channel blocker, a  $\beta$ -adrenergic receptor antagonist, a vasodilator, a diuretic, an  $\alpha$ -adrenergic receptor antagonist, an antioxidant, and a mixture thereof, wherein the 3-acylated pyridoxal analogue is a compound of the formula



wherein

$\text{R}_1$  is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

$\text{R}_2$  is a secondary amino group.

Claims 2-5. Cancelled.

Appl. No. 10/639,948  
Confirmation No. 6989  
Preliminary Amendment dated July 11, 2005

Claim 6 (Currently Amended): ~~A The method according to~~ of claim 1, wherein the calcium channel blocker is verapamil, diltiazem, nicardipine, nifedipine, amlodipine, felodipine, nimodipine, or bepridil.

Claim 7 (Currently Amended): ~~A The method according to~~ of claim 1, wherein the compound is administered enterally or parenterally and the therapeutic cardiovascular compound is administered enterally or parenterally.

Claim 8 (Currently Amended): ~~A The method according to~~ of claim 1, wherein the compound and the therapeutic cardiovascular compound are administered in a single dosage form.

Claim 9 (Currently Amended): ~~A The method according to~~ of claim 1, wherein the  $\beta$ -adrenergic receptor antagonist is atenolol, propranolol, timolol or metoprolol.

Claim 10 (Currently Amended): ~~A The method according to~~ of claim 1, wherein the diuretic is furosemide, diuril, amiloride or hydrodiuril.

Claim 11 (Currently Amended): ~~A The method according to~~ of claim 1, wherein the  $\alpha$ -adrenergic receptor antagonist is prazosin, doxazosin or labetalol.


Claim 12 (Currently Amended): ~~A The method according to~~ of claim 1, wherein the antioxidant is vitamin E, vitamin C or an isoflavone.

Claim 13 (New): A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective amount of a combination of an angiotensin converting enzyme inhibitor and a compound selected from the group consisting of pyridoxal-5'-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, wherein the 3-acylated pyridoxal analogue is a compound of the formula

Appl. No. 10/639,948

Confirmation No. 6989

Preliminary Amendment dated July 11, 2005




wherein

$R_1$  is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and

$R_2$  is a secondary amino group.

Claim 14 (New): The method according to claim 13, wherein the angiotensin converting enzyme inhibitor is captopril, enalapril, lisinopril, benzazpril, fosinopril, quinapril, ramipril, spirapril, imidapril, or moexipril.

Claim 15 (New): A method of treating hypertrophy in a mammal comprising: concurrently administering to the mammal a therapeutically effective amount of a combination of a an angiotensin II receptor antagonist and a compound selected from the group consisting of pyridoxal-5'-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, and a mixture thereof, wherein the 3-acylated pyridoxal analogue is a compound of the formula



wherein

Appl. No. 10/639,948  
Confirmation No. 6989  
Preliminary Amendment dated July 11, 2005

$R_1$  is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and  
 $R_2$  is a secondary amino group.

Claim 16 (New): The method according to claim 15, wherein the angiotensin II receptor antagonist is losartan or valsartan.